[1]劉江海.異丙托溴銨霧化吸入治療慢阻肺急性加重期的臨床療效[J].醫學信息,2019,(20):150-152.[doi:10.3969/j.issn.1006-1959.2019.20.047]
 LIU Jiang-hai.Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(20):150-152.[doi:10.3969/j.issn.1006-1959.2019.20.047]
點擊復制

異丙托溴銨霧化吸入治療慢阻肺急性加重期的臨床療效()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
150-152
欄目:
藥物與臨床
出版日期:
2019-10-15

文章信息/Info

Title:
Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章編號:
1006-1959(2019)20-0150-03
作者:
劉江海
(于都縣人民醫院醫務科,江西 于都 342300)
Author(s):
LIU Jiang-hai
(Department of Medical Affairs,Yudu County People's Hospital,Yudu 342300,Jiangxi,China)
關鍵詞:
慢阻肺急性加重期異丙托溴銨沙丁胺醇布地奈德
Keywords:
Acute exacerbation of chronic obstructive pulmonary diseaseIpratropium bromide SalbutamolBudesonide
分類號:
R563.8
DOI:
10.3969/j.issn.1006-1959.2019.20.047
文獻標志碼:
A
摘要:
目的 探討沙丁胺醇與布地奈德聯合異丙托溴銨霧化吸入治療慢阻肺急性加重期的臨床療效。方法 選取2017年7月~2019年4月我院收治的慢阻肺急性加重期患者94例,根據隨機數字表法分為觀察組和對照組,每組47例。對照組給予沙丁胺醇與布地奈德霧化吸入治療,觀察組在對照組基礎上加用異丙托溴銨霧化吸入治療,比較兩組臨床療效、不良反應總發生率及治療前后肺功能指標變化情況(FEV1%、FEV1和FVC)。結果 觀察組總有效率為91.49%,高于對照組的74.47%,差異有統計學意義(P<0.05)。觀察組不良反應總發生率為12.76%,低于對照組的14.89%,但差異無統計學意義(P>0.05)。治療后,觀察組FEV1%、FEV1和FVC均高于對照組[(70.61±14.74)% vs(61.24±13.42)%]、[(2.25±0.77)L vs(1.94±0.63)L]、[(3.46±0.98)L vs(3.07±0.91)L],差異有統計學意義(P<0.05)。結論 沙丁胺醇與布地奈德聯合異丙托溴銨霧化吸入治療慢阻肺急性加重期患者療效顯著,有助于改善患者臨床癥狀及肺部通氣功能,減少用藥后不良反應發生幾率,安全性高。
Abstract:
Objective To investigate the clinical efficacy of salbutamol and budesonide combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 94 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital from July 2017 to April 2019 were enrolled. The patients were divided into observation group and control group according to the random number table method, with 47 cases in each group. The control group was given salbutamol and budesonide inhalation treatment. The observation group was treated with ipratropium bromide inhalation treatment on the basis of the control group. The clinical efficacy, the total incidence of adverse reactions and the changes of lung function indexes before and after treatment were compared between the two groups. Situation (FEV1%, FEV1 and FVC).Results The total effective rate of the observation group was 91.49%, which was higher than that of 74.47% in the control group,the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was 12.76%, which was lower than that of 14.89% in the control group, but the difference was not statistically significant (P>0.05). After treatment, FEV1%, FEV1 and FVC in the observation group were higher than those in the control group [(70.61±14.74)% vs (61.24±13.42)%], [(2.25±0.77) L vs (1.94±0.63) L], [( 3.46±0.98) L vs (3.07±0.91) L], the difference was statistically significant (P<0.05).Conclusion Salbutamol combined with budesonide and ipratropium bromide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease is effective, which can improve the clinical symptoms and pulmonary ventilation function, reduce the incidence of adverse reactions after medication, and have high safety.

參考文獻/References:

[1]丁小山.布地奈德聯合復方異丙托溴銨霧化吸入對慢性阻塞性肺疾病急性加重期患者的臨床療效[J]. 吉林醫學,2017,38(9):1711-1712. [2]王琴,黃小紅,朱齊琦.復方異丙托溴銨霧化治療慢阻肺急性加重期患者的臨床效果分析[J].中國現代醫生,2017(34):104-106. [3]中華醫學會呼吸病學分會慢性阻塞性肺疾病學組.慢性阻塞性肺病(COPD)診治規范[J].全科醫學臨床與教育,2013,11(6):603-607 [4]章春花.布地奈德聯合異丙托溴銨霧化吸入治療慢阻肺急性加重期療效分析[J].醫學理論與實踐,2017,30(21):3185-3186. [5]成人慢性氣道疾病霧化吸入治療專家組.成人慢性氣道疾病霧化吸入治療專家共識[J].中國呼吸與危重監護雜志,2012,11(2):105-110. [6]張鳳秋.特布他林霧化液、異丙托溴銨霧化液、普米克令舒聯合霧化吸入治療慢阻肺急性加重期的療效觀察[J].中國社區醫師,2018,34(32):53-54. [7]李軍勝,馮娟.吸入噻托溴銨干粉與異丙托溴銨定量氣霧劑治療慢性阻塞性肺疾病的療效觀察[J].北方藥學,2016,13(3):105. [8]潘宜,黃曉穎.布地奈德聯合沙丁胺醇和異丙托溴銨治療慢性阻塞性肺疾病急性發作期的臨床研究[J].中國臨床藥理學雜志,2016,32(15):1347-1349. [9]邱彬,陳憲明.異丙托溴銨霧化吸入為主三聯治療慢阻肺急性加重期療效觀察[J].中國藥師,2015,18(12):2097-2099.

相似文獻/References:

[1]周 佳,柴明思.布地奈德、異丙托溴銨氣霧劑聯合霧化吸入治療對肺氣腫患者肺功能及血液相關指標的影響[J].醫學信息,2019,(09):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
 ZHOU Jia,CHAI Ming-si.Effects of Budesonide and Ipratropium Bromide Aerosol Combined with Nebulized Inhalation on Pulmonary Function and Blood Related Indexes in Patients with Emphysema[J].Medical Information,2019,(20):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
[2]章 勇,李 秀.多索茶堿治療慢性阻塞性肺疾病急性加重期患者的臨床療效[J].醫學信息,2019,(11):159.[doi:10.3969/j.issn.1006-1959.2019.11.048]
 ZHANG Yong,LI Xiu.Clinical Efficacy of Doxofylline in the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(20):159.[doi:10.3969/j.issn.1006-1959.2019.11.048]
[3]武殿香.丙酸氟替卡松聯合特布他林治療COPD急性加重期的效果[J].醫學信息,2019,(21):143.[doi:10.3969/j.issn.1006-1959.2019.21.046]
 WU Dian-xiang.Effect of Fluticasone Propionate Combined with Terbutaline on Acute Exacerbation of COPD[J].Medical Information,2019,(20):143.[doi:10.3969/j.issn.1006-1959.2019.21.046]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图